125 related articles for article (PubMed ID: 10997633)
1. Alprazolam, a benzodiazepine, blunts but does not abolish the ACTH and cortisol response to hexarelin, a GHRP, in obese patients.
Grottoli S; Arvat E; Gauna C; Maccagno B; Ramunni J; Giordano R; Maccario M; Deghenghi R; Ghigo E
Int J Obes Relat Metab Disord; 2000 Jun; 24 Suppl 2():S136-7. PubMed ID: 10997633
[TBL] [Abstract][Full Text] [Related]
2. Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.
Grottoli S; Arvat E; Gauna C; Maccagno B; Ramunni J; Giordano R; Maccario M; Deghenghi R; Ghigo E
Pituitary; 1999 Nov; 2(3):197-204. PubMed ID: 11081154
[TBL] [Abstract][Full Text] [Related]
3. Effects of dexamethasone and alprazolam, a benzodiazepine, on the stimulatory effect of hexarelin, a synthetic GHRP, on ACTH, cortisol and GH secretion in humans.
Arvat E; Maccagno B; Ramunni J; Di Vito L; Gianotti L; Broglio F; Benso A; Deghenghi R; Camanni F; Ghigo E
Neuroendocrinology; 1998 May; 67(5):310-6. PubMed ID: 9641612
[TBL] [Abstract][Full Text] [Related]
4. Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans.
Arvat E; Maccagno B; Ramunni J; Giordano R; Broglio F; Gianotti L; Maccario M; Camanni F; Ghigo E
Eur J Endocrinol; 2000 Nov; 143(5):601-6. PubMed ID: 11078983
[TBL] [Abstract][Full Text] [Related]
5. Corticotropin-releasing effect of hexarelin, a peptidyl GH secretagogue, in normal subjects pretreated with metyrapone or RU-486, a glucocorticoid receptor antagonist, and in patients with Addison's disease.
Arvat E; Ramunni J; Maccagno B; Giordano R; Broglio F; Deghenghi R; Boscaro M; Ghigo E
Neuroendocrinology; 1999 Sep; 70(3):200-6. PubMed ID: 10516483
[TBL] [Abstract][Full Text] [Related]
6. Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.
Arvat E; Di Vito L; Lanfranco F; Broglio F; Giordano R; Benso A; Muccioli GP; Deghenghi R; Ghigo E
J Endocrinol Invest; 1999 Feb; 22(2):91-7. PubMed ID: 10195374
[TBL] [Abstract][Full Text] [Related]
7. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
[TBL] [Abstract][Full Text] [Related]
8. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.
Maccario M; Veldhuis JD; Broglio F; Vito LD; Arvat E; Deghenghi R; Ghigo E
Eur J Endocrinol; 2002 Mar; 146(3):310-8. PubMed ID: 11888836
[TBL] [Abstract][Full Text] [Related]
9. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
Arvat E; di Vito L; Maccagno B; Broglio F; Boghen MF; Deghenghi R; Camanni F; Ghigo E
Peptides; 1997; 18(6):885-91. PubMed ID: 9285939
[TBL] [Abstract][Full Text] [Related]
10. Influence of galanin and serotonin on the endocrine response to Hexarelin, a synthetic peptidyl GH-secretagogue, in normal women.
Arvat E; Maccagno B; Ramunni J; Broglio F; Lanfranco F; Giordano R; Benso A; Deghenghi R; Ghigo E
J Endocrinol Invest; 1998 Nov; 21(10):673-9. PubMed ID: 9854683
[TBL] [Abstract][Full Text] [Related]
11. The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations.
Arvat E; Ramunni J; Bellone J; Di Vito L; Baffoni C; Broglio F; Deghenghi R; Bartolotta E; Ghigo E
Eur J Endocrinol; 1997 Dec; 137(6):635-42. PubMed ID: 9437229
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.
Gianotti L; Ramunni J; Lanfranco F; Maccagno B; Giordano R; Broglio F; Maccario M; Muller EE; Ghigo E; Arvat E
J Endocrinol Invest; 2001 Feb; 24(2):67-71. PubMed ID: 11263473
[TBL] [Abstract][Full Text] [Related]
13. Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease.
Arvat E; Ramunni J; Giordano R; Maccagno B; Broglio F; Benso A; Deghenghi R; Ghigo E
J Endocrinol Invest; 1999 Jan; 22(1):23-8. PubMed ID: 10090133
[TBL] [Abstract][Full Text] [Related]
14. Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans.
Arvat E; Maccagno B; Ramunni J; Di Vito L; Broglio F; Deghenghi R; Camanni F; Ghigo E
Neuroendocrinology; 1997 Dec; 66(6):432-8. PubMed ID: 9430449
[TBL] [Abstract][Full Text] [Related]
15. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
[TBL] [Abstract][Full Text] [Related]
16. Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity.
Grottoli S; Maccario M; Procopio M; Oleandri SE; Arvat E; Gianotti L; Deghenghi R; Camanni F; Ghigo E
Eur J Endocrinol; 1996 Dec; 135(6):678-82. PubMed ID: 9025712
[TBL] [Abstract][Full Text] [Related]
17. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
[TBL] [Abstract][Full Text] [Related]
18. Glucagon administration elicits blunted GH but exaggerated ACTH response in obesity.
Tassone F; Grottoli S; Rossetto R; Maccagno B; Gauna C; Giordano R; Ghigo E; Maccario M
J Endocrinol Invest; 2002 Jun; 25(6):551-6. PubMed ID: 12109628
[TBL] [Abstract][Full Text] [Related]
19. Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans.
Grottoli S; Maccagno B; Ramunni J; Di Vito L; Giordano R; Gianotti L; DeStefanis S; Camanni F; Ghigo E; Arvat E
J Endocrinol Invest; 2002 May; 25(5):420-5. PubMed ID: 12035937
[TBL] [Abstract][Full Text] [Related]
20. Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin-induced hypoglycaemia in humans.
Giordano R; Grottoli S; Brossa P; Pellegrino M; Destefanis S; Lanfranco F; Gianotti L; Ghigo E; Arvat E
Clin Endocrinol (Oxf); 2003 Sep; 59(3):314-20. PubMed ID: 12919154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
